Integrum AB Series B Net Assets

Latest as of June 2026: Skr174.19 Million SEK ≈ $18.75 Million USD

Integrum AB Series B net assets. Based on the latest financial reports, Integrum AB Series B (INTEG-B) has net assets worth Skr174.19 Million SEK (≈ $18.75 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr199.15 Million ≈ $21.43 Million USD) and total liabilities (Skr24.96 Million ≈ $2.69 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of Integrum AB Series B to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric Value
Current Net Assets Skr174.19 Million
% of Total Assets 87.47%
Annual Growth Rate 40.04%
5-Year Change 7.68%
10-Year Change 1532.82%
Growth Volatility 263.77

Net Assets of Integrum AB Series B (2013–2025)

Net assets of Integrum AB Series B from 2013 to 2025. This chart illustrates how Integrum AB Series B's net assets have evolved over time, based on quarterly financial data. See net asset quality index of Integrum AB Series B to measure how much of total assets are equity-financed.

Annual Net Assets for Integrum AB Series B (2013–2025)

The table below shows the annual net assets of Integrum AB Series B from 2013 to 2025. For live market cap and overall valuation, see market cap of Integrum AB Series B.

Year Net Assets Change
2025-12-31 Skr172.01 Million
≈ $18.51 Million
-3.30%
2024-12-31 Skr177.88 Million
≈ $19.14 Million
+24.57%
2023-12-31 Skr142.79 Million
≈ $15.37 Million
-0.52%
2022-12-31 Skr143.53 Million
≈ $15.45 Million
-10.15%
2021-12-31 Skr159.74 Million
≈ $17.19 Million
+557.52%
2020-12-31 Skr24.29 Million
≈ $2.61 Million
+2.39%
2019-12-31 Skr23.73 Million
≈ $2.55 Million
+47.82%
2018-12-31 Skr16.05 Million
≈ $1.73 Million
-10.84%
2017-12-31 Skr18.00 Million
≈ $1.94 Million
+70.90%
2016-12-31 Skr10.53 Million
≈ $1.13 Million
+828.13%
2015-12-31 Skr1.14 Million
≈ $122.14K
+0.09%
2014-12-31 Skr1.13 Million
≈ $122.04K
-62.51%
2013-12-31 Skr3.02 Million
≈ $325.48K
--

Equity Component Analysis

This analysis shows how different components contribute to Integrum AB Series B's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 3950.8% over the analyzed period, potentially due to dividend distributions or operating losses.

Integrum AB Series B Net Assets Breakdown (December 2025)

Integrum AB Series B net assets breakdown by equity component as of December 2025.

Component Amount Percentage
Common Stock Skr1.87 Million 1.09%
Other Comprehensive Income Skr-18.34 Million -10.66%
Other Components Skr301.09 Million 175.05%
Total Equity Skr172.01 Million 100.00%

Integrum AB Series B Competitors by Market Cap

The table below lists competitors of Integrum AB Series B ranked by their market capitalization.

Company Market Cap
Shiva Texyarn Limited
NSE:SHIVATEX
$23.25 Million
Okong Corporation
KQ:045060
$23.25 Million
LS telcom AG
XETRA:LSX
$23.29 Million
Aspermont Ltd
AU:ASP
$23.29 Million
Trisula Textile Industries Tbk PT
JK:BELL
$23.24 Million
DLSI
PA:ALDLS
$23.24 Million
Range Capital Acquisition Corp. Ordinary Shares
NASDAQ:RANG
$23.23 Million
CNTus Sungjin Co. Ltd.
KQ:352700
$23.22 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Integrum AB Series B's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 177,875,000 to 172,007,000, a change of -5,868,000 (-3.3%).
  • Net loss of 46,337,000 reduced equity.
  • New share issuances of 37,933,000 increased equity.
  • Other comprehensive income increased equity by 2,751,551.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income Skr-46.34 Million -26.94%
Share Issuances Skr37.93 Million +22.05%
Other Comprehensive Income Skr2.75 Million +1.6%
Other Changes Skr-215.55K -0.13%
Total Change Skr- -3.30%

Book Value vs Market Value Analysis

This analysis compares Integrum AB Series B's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.13x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 27.23x to 1.13x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2013-12-31 Skr0.30 Skr8.30 x
2014-12-31 Skr0.11 Skr8.30 x
2015-12-31 Skr0.11 Skr8.30 x
2016-12-31 Skr1.18 Skr8.30 x
2017-12-31 Skr1.81 Skr8.30 x
2018-12-31 Skr1.28 Skr8.30 x
2019-12-31 Skr1.57 Skr8.30 x
2020-12-31 Skr1.53 Skr8.30 x
2021-12-31 Skr8.79 Skr8.30 x
2022-12-31 Skr7.83 Skr8.30 x
2023-12-31 Skr7.41 Skr8.30 x
2024-12-31 Skr8.34 Skr8.30 x
2025-12-31 Skr7.34 Skr8.30 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Integrum AB Series B utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -26.94%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -50.71%
  • • Asset Turnover: 0.45x
  • • Equity Multiplier: 1.18x
  • Recent ROE (-26.94%) is above the historical average (-28.24%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2013 56.82% 9.05% 2.20x 2.86x Skr1.42 Million
2014 0.02% 0.00% 2.31x 5.66x Skr-113.22K
2015 0.02% 0.00% 1.21x 8.96x Skr-113.30K
2016 -54.54% -32.26% 0.90x 1.88x Skr-6.80 Million
2017 -101.97% -120.99% 0.58x 1.47x Skr-20.16 Million
2018 -153.16% -109.50% 0.90x 1.55x Skr-26.19 Million
2019 -66.11% -58.65% 0.83x 1.36x Skr-18.06 Million
2020 -8.81% -4.97% 1.16x 1.53x Skr-4.57 Million
2021 13.32% 38.17% 0.31x 1.13x Skr5.30 Million
2022 -11.27% -21.79% 0.45x 1.15x Skr-30.53 Million
2023 2.82% 3.87% 0.63x 1.15x Skr-10.25 Million
2024 -17.34% -33.87% 0.45x 1.14x Skr-48.64 Million
2025 -26.94% -50.71% 0.45x 1.18x Skr-63.54 Million

Industry Comparison

This section compares Integrum AB Series B's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $416,764,988
  • Average return on equity (ROE) among peers: -38.93%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Integrum AB Series B (INTEG-B) Skr174.19 Million 56.82% 0.14x $23.25 Million
Acarix A/S (ACARIX) $38.17 Million -125.99% 0.27x $24.00 Million
Arcoma AB (ARCOMA) $44.04 Million -16.97% 0.80x $12.32 Million
Bactiguard Holding AB (publ) (BACTI-B) $373.35 Million -10.28% 0.81x $51.45 Million
BICO Group AB (BICO) $3.10 Billion -37.83% 0.95x $179.52 Million
Boule Diagnostics AB (BOUL) $462.50 Million 2.75% 0.64x $4.97 Million
CellaVision AB (CEVI) $66.67 Million 0.00% 0.27x $512.85 Million
Clinical Laserthermia Systems AB (publ) (CLS-B) $19.46 Million -85.28% 0.14x $9.20 Million
Chordate Medical Holding AB (CMH) $29.55 Million -46.39% 0.39x $29.05K
C-Rad AB (publ) (CRAD-B) $29.82 Million -34.38% 0.50x $82.28 Million
Duearity AB (DEAR) $3.79 Million -34.93% 0.15x $331.97K

About Integrum AB Series B

ST:INTEG-B Sweden Medical Devices
Market Cap
$23.25 Million
Skr216.03 Million SEK
Market Cap Rank
#24464 Global
#478 in Sweden
Share Price
Skr8.30
Change (1 day)
+1.22%
52-Week Range
Skr6.96 - Skr11.80
All Time High
Skr102.00
About

Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses. The company provides prostheses for the Rehabilitation of Amputees (OPRA) implant systems, a bone-anchored prostheses system based on osseointegration, where the prostheses are directly attached to the bone, avoiding the use of socket. The OPRA implant system offers protection to the patient by avoidi… Read more